• Steven D Passik, Kenneth L Kirsh, and Robert K Twillman.
• Millennium Research Institute, San Diego,California; Vice President, Clinical Research and Advocacy, Millennium Health, San Diego, California.
• J Opioid Manag. 2015 Jan 1;11(1):77-81.

ObjectiveBoth prescription drug monitoring programs (PDMP) and urine drug testing (UDT) are recommended as parts of an ongoing risk management approach for controlled substance prescribing. The authors provide an editorial and commentary to discuss the unique contributions of each to promote better clinical decision making for prescribers.DesignA commentary is employed along with brief discussion comparing four states with an active PDMP in place to three states without an active PDMP as it relates back to findings on UDT in those states from a laboratory conducting liquid chromatography tandem mass spectrometry.ConclusionsThe commentary focuses on the place of both tools (UDT and PDMP) in risk management efforts. The argument is made that relying on a PDMP alone would lead to clinical decisions that may miss a great deal of problematic or aberrant behaviors.

36 keywords...

hide…